Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.45
SPNC's Cash to Debt is ranked higher than
56% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.27 vs. SPNC: 0.45 )
SPNC' s 10-Year Cash to Debt Range
Min: 0.45   Max: No Debt
Current: 0.45

Equity to Asset 0.37
SPNC's Equity to Asset is ranked higher than
51% of the 453 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. SPNC: 0.37 )
SPNC' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.89
Current: 0.37

0.37
0.89
Interest Coverage No Debt
SPNC's Interest Coverage is ranked higher than
70% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 241.11 vs. SPNC: No Debt )
SPNC' s 10-Year Interest Coverage Range
Min: 1.05   Max: 9999.99
Current: No Debt

1.05
9999.99
F-Score: 3
Z-Score: 2.98
M-Score: -2.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -11.64
SPNC's Operating margin (%) is ranked higher than
59% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 5.49 vs. SPNC: -11.64 )
SPNC' s 10-Year Operating margin (%) Range
Min: -60.53   Max: 4.35
Current: -11.64

-60.53
4.35
Net-margin (%) -13.75
SPNC's Net-margin (%) is ranked higher than
59% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. SPNC: -13.75 )
SPNC' s 10-Year Net-margin (%) Range
Min: -93.86   Max: 23.17
Current: -13.75

-93.86
23.17
ROE (%) -13.74
SPNC's ROE (%) is ranked higher than
59% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 5.07 vs. SPNC: -13.74 )
SPNC' s 10-Year ROE (%) Range
Min: -44.49   Max: 29.8
Current: -13.74

-44.49
29.8
ROA (%) -7.96
SPNC's ROA (%) is ranked higher than
61% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.61 vs. SPNC: -7.96 )
SPNC' s 10-Year ROA (%) Range
Min: -28.33   Max: 18.38
Current: -7.96

-28.33
18.38
ROC (Joel Greenblatt) (%) -38.74
SPNC's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 8.37 vs. SPNC: -38.74 )
SPNC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -90.13   Max: 27.96
Current: -38.74

-90.13
27.96
Revenue Growth (%) 4.60
SPNC's Revenue Growth (%) is ranked higher than
72% of the 339 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. SPNC: 4.60 )
SPNC' s 10-Year Revenue Growth (%) Range
Min: -7.6   Max: 29.4
Current: 4.6

-7.6
29.4
EBITDA Growth (%) 46.00
SPNC's EBITDA Growth (%) is ranked higher than
97% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. SPNC: 46.00 )
SPNC' s 10-Year EBITDA Growth (%) Range
Min: -53.6   Max: 81.7
Current: 46

-53.6
81.7
EPS Growth (%) -70.50
SPNC's EPS Growth (%) is ranked lower than
51% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. SPNC: -70.50 )
SPNC' s 10-Year EPS Growth (%) Range
Min: -70.5   Max: 101.7
Current: -70.5

-70.5
101.7
» SPNC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

SPNC Guru Trades in Q4 2013

Ron Baron 10,780 sh (New)
Jim Simons 70,222 sh (+9.72%)
Paul Tudor Jones Sold Out
Chuck Royce Sold Out
Steven Cohen 420,051 sh (-35.1%)
» More
Q1 2014

SPNC Guru Trades in Q1 2014

Ron Baron 36,980 sh (+243.04%)
Jim Simons 103,528 sh (+47.43%)
Steven Cohen 40,000 sh (unchged)
Steven Cohen 128,871 sh (-69.32%)
» More
Q2 2014

SPNC Guru Trades in Q2 2014

Ron Baron 60,480 sh (+63.55%)
Jim Simons Sold Out
» More
Q3 2014

SPNC Guru Trades in Q3 2014

Ron Baron 309,727 sh (+412.11%)
» More
» Details

Insider Trades

Latest Guru Trades with SPNC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2014-09-30 Add 412.11%0.03%$22.76 - $29.33 $ 32.2920%309727
Ron Baron 2014-06-30 Add 63.55%$20.78 - $29.79 $ 32.2939%60480
Ron Baron 2014-03-31 Add 243.04%$24.13 - $31.56 $ 32.2918%36980
Ron Baron 2013-12-31 New Buy$17.2 - $25.43 $ 32.2951%10780
George Soros 2011-09-30 Sold Out 0.0012%$5.6 - $7.62 $ 32.29396%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Spectranetics Corp

Baron Funds Comments on Spectranetics Corporation - Feb 26, 2014

The Spectranetics Corporation (SPNC) is a manufacturer of medical devices that assist in the treatment of peripheral arterial disease and also with the removal of coronary leads used for implanted devices such as pacemakers and defibrillators. Shares were up 46% in the quarter. Most of the company's devices use disposable products that lead to a highly recurring revenue stream. The company is on the verge of opening up large new markets with the expected 2014 approval of a new laser based device that can open up arteries that have previously been stented. If approved, it will be the only device on the market that has this capability.



From Ron Baron (Trades, Portfolio)'s Baron Funds fourth quarter 2013 letter to shareholders.

Check out Ron Baron latest stock trades

Top Ranked Articles about Spectranetics Corp

Baron Funds Comments on Spectranetics Corporation
The Spectranetics Corporation (SPNC) is a manufacturer of medical devices that assist in the treatment of peripheral arterial disease and also with the removal of coronary leads used for implanted devices such as pacemakers and defibrillators. Shares were up 46% in the quarter. Most of the company's devices use disposable products that lead to a highly recurring revenue stream. The company is on the verge of opening up large new markets with the expected 2014 approval of a new laser based device that can open up arteries that have previously been stented. If approved, it will be the only device on the market that has this capability. Read more...

Ratios

vs
industry
vs
history
P/B 7.90
SPNC's P/B is ranked higher than
56% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.78 vs. SPNC: 7.90 )
SPNC' s 10-Year P/B Range
Min: 0.78   Max: 13.1
Current: 7.9

0.78
13.1
P/S 7.30
SPNC's P/S is ranked higher than
60% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. SPNC: 7.30 )
SPNC' s 10-Year P/S Range
Min: 0.69   Max: 8.47
Current: 7.3

0.69
8.47
EV-to-EBIT -69.42
SPNC's EV-to-EBIT is ranked lower than
60% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 73.45 vs. SPNC: -69.42 )
SPNC' s 10-Year EV-to-EBIT Range
Min: -4632.7   Max: 2801.8
Current: -69.42

-4632.7
2801.8
Current Ratio 5.23
SPNC's Current Ratio is ranked higher than
86% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. SPNC: 5.23 )
SPNC' s 10-Year Current Ratio Range
Min: 1.39   Max: 8.52
Current: 5.23

1.39
8.52
Quick Ratio 4.43
SPNC's Quick Ratio is ranked higher than
85% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. SPNC: 4.43 )
SPNC' s 10-Year Quick Ratio Range
Min: 1.2   Max: 7.99
Current: 4.43

1.2
7.99

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 13.20
SPNC's Price/DCF (Projected) is ranked higher than
80% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. SPNC: 13.20 )
SPNC' s 10-Year Price/DCF (Projected) Range
Min: 5.23   Max: 336.5
Current: 13.2

5.23
336.5
Price/Median PS Value 1.80
SPNC's Price/Median PS Value is ranked higher than
61% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. SPNC: 1.80 )
SPNC' s 10-Year Price/Median PS Value Range
Min: 0.19   Max: 1.89
Current: 1.8

0.19
1.89
Earnings Yield (Greenblatt) -1.40
SPNC's Earnings Yield (Greenblatt) is ranked higher than
65% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. SPNC: -1.40 )
SPNC' s 10-Year Earnings Yield (Greenblatt) Range
Min: -1.4   Max: 31.1
Current: -1.4

-1.4
31.1
Forward Rate of Return (Yacktman) -0.16
SPNC's Forward Rate of Return (Yacktman) is ranked higher than
75% of the 349 Companies
in the Global Medical Devices industry.

( Industry Median: 0.59 vs. SPNC: -0.16 )
SPNC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -5.8   Max: 13.9
Current: -0.16

-5.8
13.9

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:SC7.Germany
Spectranetics Corp is incorporated under the laws of Delaware and formed in 1984. The Company develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company has two operating segments that are identified on a geographic basis: U.S. Medical and International Medical. U.S. Medical and International Medical offer the same products and services but operate in different geographic regions, have different distribution networks and different regulatory environments. Its products are used to treat arterial blockages in the heart and legs and to remove pacemaker and defibrillator cardiac leads. Approximately 68% of its disposable product revenue is from products used in connection with its proprietary excimer laser system, the CVX-300. Its single-use laser catheters contain up to 250 small diameters, flexible optical fibers that can access difficult to reach peripheral and coronary anatomy and produce evenly distributed laser energy at the tip of the catheter for more uniform ablation. Its disposable products are develops in two categories: Vascular Intervention (VI) and Lead Management (LM). Vascular Intervention products include; support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions, drug delivery catheters for vascular delivery of drugs and diagnostic agents. Lead Management products include: excimer laser sheaths; non-laser sheaths; and cardiac lead management accessories for the removal of pacemaker and defibrillator cardiac leads. Its competitors are manufacturers of products used in competing therapies within the peripheral and coronary atherectomy markets, such as: atherectomy and thrombectomy, using mechanical methods to remove arterial blockages, balloon angioplasty and stents, specialty balloon angioplasty, bypass surgery and amputation. The Company's products are medical devices subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act, or FDCA. FDA regulations govern.
» More Articles for SPNC

Headlines

Articles On GuruFocus.com
Baron Funds Comments on Spectranetics Corporation Feb 26 2014 
Spectranetics Corp. Reports Operating Results (10-Q) Nov 08 2010 
Spectranetics Corp. Reports Operating Results (10-Q) Nov 06 2009 
Spectranetics Corp. Reports Operating Results (10-Q) Aug 10 2009 
Spectranetics Corp. Reports Operating Results (10-Q) May 11 2009 
Spectranetics to Hold 2008 Fourth Quarter Financial Results Conference Call on February 19 Feb 12 2009 
Spectranetics Cross-Pilot Product Receives FDA Clearance Dec 15 2008 
Weekly CEO Buys Highlight: Spectranetics Corp., Noven Pharmaceuticals Inc., Dolan Media Company, Mod Sep 09 2008 

More From Other Websites
FTC approves Medtronic acquisition of Covidien Nov 26 2014
SPECTRANETICS CORP Files SEC form 8-K, Regulation FD Disclosure Nov 26 2014
Medtronic gets U.S. antitrust OK to buy Covidien with divestiture Nov 26 2014
Medtronic gets U.S. antitrust OK to buy Covidien with divestiture Nov 26 2014
Covidien, Medtronic Shareholders Poised for January Vote Nov 25 2014
Covidien and Medtronic Shareholders Set for a January Vote Nov 25 2014
Spectranetics to Host Investor & Analyst Meeting Nov 17 2014
Spectranetics to Host Investor & Analyst Meeting Nov 17 2014
SPECTRANETICS CORP Financials Nov 14 2014
The Spectranetics (SPNC): Strong Industry, Solid Earnings Estimate Revisions Nov 14 2014
10-Q for The Spectranetics Corp. Nov 08 2014
SPECTRANETICS CORP Files SEC form 10-Q, Quarterly Report Nov 06 2014
Insider Trading Alert - CCL, SYRG And SPNC Traded By Insiders Nov 06 2014
Spectranetics to Participate in Upcoming Investor Conferences Nov 05 2014
Spectranetics to Participate in Upcoming Investor Conferences Nov 05 2014
Can The Spectranetics (SPNC) Keep the Earnings Streak Alive This Quarter? Nov 04 2014
SPECTRANETICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD... Nov 03 2014
Spectranetics to Acquire Stellarex™ Drug Coated Balloon Assets From Covidien Nov 02 2014
Spectranetics to Acquire Stellarex(TM) Drug Coated Balloon Assets From Covidien Nov 02 2014
Spectranetics to Acquire Stellarex(TM) Drug Coated Balloon Assets From Covidien Nov 02 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK